Type 2 Diabetes

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.

In this week's Homerun Slides, a summary of the clinical trials assessing the impact of intensive therapy in type 2 diabetes.

New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.

Results determined for 3-year study of liraglutide versus placebo diabetes risk reduction and weight management in individuals with prediabetes.

Study focused on type 2 diabetes patients who initiate metformin.

Study focuses on elevation of amylase and lipase levels as predictors of pancreatitis.

A proposed benefit of GLP-1 agonists confirmed in a human study.

Retrospective analysis presentation shows liraglutide (LIRA) improved glycemic parameters, reduced body weight, BMI, and waist circumference in new T2 patients.

More rigorous screening called for to mitigate poor outcomes of this common condition.